Catecholamine-secreting paragangliomas (PGLs) are rare neoplasms of neuroendocrine origin. Overall, less than 2% of PGLs are mediastinal. 1,2 There have been less than 200 cases of intrapericardial PGLs reported in the literature. 3 It is now understood that up to 50% of PGL is familial. 4 Several genetic conditions are associated with PGL/phaeochromocytoma including the multiple endocrine neoplasia type 2 syndromes, von Hippel-Lindau disease, neurofibromatosis, and the succinate dehydrogenase germline mutations (SDHx). Mutation in succinate dehydrogenase predisposes patients to both non-functioning and catecholamine-secreting PGL and phaeochromocytoma through a mechanism involving induction of hypoxia-inducible factor. Primary cardiac PGL associated with succinate dehydrogenase subunit B (SDHB) mutation has been described before, with four reported cases. 5 While most tumours are benign, they do have malignant potential 1 (especially those associated with succinate dehydrogenase subunit A (SDHA) and SDHB mutations) and secretory tumours expose patients to the risks of catecholamine excess.
Introduction
Catecholamine-secreting paragangliomas (PGLs) are rare neoplasms of neuroendocrine origin. Overall, less than 2% of PGLs are mediastinal. 1, 2 There have been less than 200 cases of intrapericardial PGLs reported in the literature. 3 It is now understood that up to 50% of PGL is familial. 4 Several genetic conditions are associated with PGL/phaeochromocytoma including the multiple endocrine neoplasia type 2 syndromes, von Hippel-Lindau disease, neurofibromatosis, and the succinate dehydrogenase germline mutations (SDHx). Mutation in succinate dehydrogenase predisposes patients to both non-functioning and catecholamine-secreting PGL and phaeochromocytoma through a mechanism involving induction of hypoxia-inducible factor. Primary cardiac PGL associated with succinate dehydrogenase subunit B (SDHB) mutation has been described before, with four reported cases. 5 While most tumours are benign, they do have malignant potential 1 (especially those associated with succinate dehydrogenase subunit A (SDHA) and SDHB mutations) and secretory tumours expose patients to the risks of catecholamine excess.
Case
We present a single case of a 34-year-old male referred to our service from the endocrinology department after discovery of a mediastinal mass. The patient had a family history of SDHB mutation, with two cousins having undergone carotid body PGL resection. The patient first presented to the endocrinology clinic after familial cascade genetic screening diagnosed an SDHB mutation. Over the previous several years, he had experienced daily palpitations, headache, diaphoresis, anxiety, and central chest pain. These symptoms would present unexpectedly, were unrelated to exertion, and were short lasting. He had presented multiple times to the emergency department with chest pain, with electrocardiographic, troponin studies, and stress testing being unremarkable. The patient otherwise had no past medical history.
On examination, the patient was normotensive with a regular heart rate. Plasma metanephrines were elevated and testing undertaken 2 months prior to surgery revealed that noradrenaline and dopamine were markedly elevated with Resection of a functioning intrapericardial paraganglioma associated with succinate dehydrogenase B mutation normetanephrine at 3587 pmol/L (<900 pmol/L) and 3-methoxytyramine 1075 pmol/L (<110 pmol/L).
Initial investigation with F-fluorodeoxyglucose (FDG) positron emission tomography (PET) discovered an intense uptake in the left lateral aspect of the aortic root inferior to the pulmonary artery (Figure 1(a) ). This was further clarified using contrast-enhanced computed tomography and cardiac magnetic resonance imaging (MRI; Figure 1 (b) and (c)).
These revealed a 35 mm × 34 mm × 29 mm mass adjacent to the aortic root posterior to the pulmonary artery. MRI was suggestive that this lesion was not invading the myocardium. Whole-body metaiodobenzylguanidine (mIBG) scintigraphy did not reveal any metabolic lesion suspicious for metastasis. Transthoracic echocardiography was negative for impedance of this lesion on cardiac function or great vessel flow.
Preoperative medical stabilisation was achieved 1 month preoperatively using phenoxybenzamine 30 mg three times daily as alpha blockade and subsequently beta blockade with metoprolol 25 mg twice daily was added 1 week prior to surgery. At surgery, the patient underwent a midline sternotomy. The tumour was unable to be easily or safely accessed with the heart full and ejecting. The distal ascending aorta and the right atrium were cannulated and the patient was placed on cardiopulmonary bypass and cooled to 32°C, and after aortic cross clamping the heart was arrested with tepid blood antegrade cardioplegia. Findings were of a 3.5 cm × 3.5 cm × 3 cm firm spherical mass located between the aortic root and pulmonary artery. Inferiorly, there was a close relation to the left main coronary artery and the circumflex artery, with the right pulmonary artery superiorly. The aortic cross clamp and cardiopulmonary bypass times were 27 and 79 min, respectively (Figure 2) .
Pathological examination was typical of PGL. Macroscopically, the specimen consisted of a 30 mm × 30 mm × 30 mm tan-coloured nodule weighing 14 g ( Figure  3(a) ). The tumour cells were positive for synaptophysin chromogranin and S-100 markers. Mitotic activity was low; however, intracytoplasmic hyaline globules were not apparent. The capsule was seen to be infiltrated by tumour cells (Figure 3(b) ).
The patient's recovery was unremarkable and he was discharged from hospital on the 5th postoperative day. At surgical follow-up, the patient reported improved symptomatology. Repeat plasma metanephrines and chromogranin A had 
Discussion
PGLs arise from neural crest tissue and the majority are benign. 3 This rare neoplasm represents about 1%-3% of cardiac tumours. 6 They are classified as being either functional or non-functional and patients will present with either symptoms of catecholamine excess or mass effect on surrounding structures. 7 As is the case with this patient, they may also present from genetic screening investigations. Aside from the presence of malignant appearing tissue in areas where paraganglion tissue is usually absent, there exists no standardised criterion for the differentiation of benign from malignant PGL. 8 Diagnosis of intrapericardial PGL can be challenging and various biochemical and imaging techniques have been used. Plasma metanephrine and normetanephrine are the metabolites of adrenaline and noradrenaline, respectively, and have been used in diagnosis of catecholamine-producing tumours. 3-Methoxytyramine is the breakdown product of dopamine and, as a diagnostic test, has been shown to modestly increase sensitivity of diagnosis of PGL. 9 FDG PET has a role in identifying these tumours. 10 Increasingly, 68-Gallium somatostatin analogue PET scanning such as DOTA-TATE is being used for PGL, with superior sensitivity over FDG scans in these lesions due to their expression of somatostatin receptors. 11, 12 Cardiac MRI plays an important role in delineating invasion into the myocardium. Coronary angiography can also be employed to rule out compression or invasion of the coronary circulation, as well as assist in surgical planning.
SDHB mutation, as in the case highlighted, is an autosomal dominant syndrome and predisposes the individual to PGL, phaeochromocytoma, and renal cell carcinoma. Compared to the other SDHx mutations, SDHB poses a higher morbidity and mortality associated with their higher malignancy rate. 13, 14 A meta-analysis by Van Hulsteijn et al. 15 found a malignancy rate of 17% for PGL associated with SDHB mutation. For these reasons, surgical resection remains the gold standard and in most cases requires median sternotomy and cardiopulmonary bypass due to relation of cardiac PGL to the coronary and great vessels. 3 We report resection and biochemical cure of an intrapericardial PGL associated with SDHB mutation. Clear margins were not observed under pathological assessment, and histological features raised concern for malignant disease, especially in a patient with SDHB mutation syndrome. However, in this disease malignancy can only be confirmed by the presence of metastases, of which our patient has no evidence. He will require close ongoing follow-up in the future. 
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